3 Comments
Apr 26, 2022Liked by Christina Ren, MS, CGC

Great work Christina! Two other broad points you might consider are, firstly, the many attractive markets continually opening up for TWST eg CRISPR screening, MRD, bispecific MaB, etc and secondly, the calibre and quality of management. Also, there is a huge tailwind when price reduction in sequencing pushes up volumes. Sequencing and synthesis are joint in the hip.

Expand full comment